EnglishFrançais

Ce site a été mis à jour le 14 mars 2017

Imprimer
Nouvelles de l'EMA

European Medicines Agency starts safety review of Combined hormonal contraceptives containing chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin or norgestimate

Following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), the European Medicines Agency has started two safety reviews:

Combined hormonal contraceptives containing chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin or norgestimate

The review of these contraceptives was requested by the French medicines agency ANSM following concerns in France about the risk of venous thromboembolism (VTE or blood clots in veins). The EMA will now review all available data on the risk of VTE with these contraceptives and issue an opinion on whether any changes are needed to their prescribing advice across the EU.

The press release is available for consultation by clicking here.

 
Сделайте правильный выбор! Онлайн или реальные слоты? Играйте на реальные деньги!
займ онлайн